-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-504713-76-00
5
2024-12-03
Dermatitis atopic
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-513009-30-00
4
2024-11-21
Moderate to Severe Crohn’s Disease
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2024-512520-11-00
9
2024-11-19
Triple negative breast cancer (TNBC)
-
2023-507899-47-00
4
2024-10-22
Cytologic or molecular relapsed/refractory CD38 positive T-cell acute
-
2023-508811-21-00
10
2024-09-25
Refractory Focal Onset Epilepsy
-
2024-512459-19-00
6
2024-09-13
Psoriatic arthritis
-
2023-507692-21-00
3
2024-08-22
Bullous pemphigoid
-
2023-503705-10-00
6
2024-08-19
Dementia in Pick disease
-
2023-507925-41-00
5
2024-08-14
Scabies
-
2023-503859-10-00
5
2024-08-12
Moderate to Severe Plaque Psoriasis
-
2023-507654-33-00
9
2024-08-12
Refractory systemic lupus erythematosus (SLE)
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
-
2023-506150-21-00
4
2024-05-29
Celiac Disease
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2022-501648-14-00
9
2024-05-05
Relapsed or refractory CD19 positive B cell malignancies (adult ALL, a
-
2022-501725-21-00
1
2024-04-12
Neuroblastoma
-
2024-515267-59-00
4
2024-04-07
Acute myeloid leukemia
-
2023-504863-17-00
5
2024-02-21
1. Lupus Erythematosus, Cutaneous, Subacute
2. Chronic Cutaneous Lupus
-
2024-516634-35-00
6
2024-02-01
Convulsive or nonconvulsive benzodiazepine-resistant (established) sta
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2023-504807-94-00
7
2023-12-26
Breast Cancer; Advanced solid tumors including but not limited to gyne